The present disclosure relates to targeted drug conjugates comprising ALK5 inhibitors and targeting moieties that direct the ALK5 inhibitors to cells involved in fibrosis and cancer, for example myofibroblasts, activated fibroblasts and transitioning fibr
-
Paragraph 0191; 0197-0198
(2021/07/17)
ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.
-
Paragraph 0183; 0189-0190
(2020/02/06)
ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.
-
Paragraph 0199; 0205-0206
(2020/06/07)
ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.
-
Paragraph 0188; 0194; 0195
(2021/01/21)
Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor i (TGFβRI)
Inhibition of transforming growth factor β (TGFβ) type I receptor (Alk5) offers a novel approach for the treatment of fibrotic diseases and cancer. Indolinones substituted in position 6 were identified as a new chemotype inhibiting TGFβRI concomitant with
Roth, Gerald J.,Heckel, Armin,Brandl, Trixi,Grauert, Matthias,Hoerer, Stefan,Kley, Joerg T.,Schnapp, Gisela,Baum, Patrick,Mennerich, Detlev,Schnapp, Andreas,Park, John E.
supporting information; experimental part
p. 7287 - 7295
(2011/02/23)
More Articles about upstream products of 1253768-91-0